L474 Pill - green oval
Generic Name: umbralisib
Pill with imprint L474 is Green, Oval and has been identified as Ukoniq 200 mg. It is supplied by TG Therapeutics, Inc.
Ukoniq is used in the treatment of Follicular Lymphoma; Marginal Zone Lymphoma and belongs to the drug class multikinase inhibitors. Ukoniq 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for L474
Ukoniq
- Generic Name
- umbralisib
- Imprint
- L474
- Strength
- 200 mg
- Color
- Green
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- TG Therapeutics, Inc.
- National Drug Code (NDC)
- 73150-0200 (Discontinued)
See also:
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Epkinly
Epkinly is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Ruxience
Ruxience is a biosimilar to Rituxan and is used to treat certain leukemias and lymphomas and some ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Gazyva
Gazyva is used to treat chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) in adults ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Rituxan Hycela
Rituxan Hycela (rituximab and hyaluronidase) is used to treat follicular lymphoma, diffuse large ...
More about Ukoniq (umbralisib)
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.